在血液透析患者的双价SARS-CoV-2mRNA疫苗接种后,活病毒血清中和
Louise Benning1, Marie Bartenschlager2, Heeyoung Kim2
1Department of Nephrology, University of Heidelberg, Heidelberg, Germany.
Journal of medical virology
|December 12, 2023
概括
双对应的COVID-19疫苗可能会在没有先前感染的血液透析患者中增强抗体反应. 然而,那些先前感染的人在双价增强剂后,免疫反应没有显著增加.
科学领域:
- 免疫学 免疫学 免疫学
- 疫苗学 疫苗学 疫苗学
- 腎臟病學 (nephrology) 是一種醫學.
背景情况:
- 双价增强剂疫苗针对正在演变的SARS-CoV-2 Omicron变种,这些变种可以逃避现有的免疫力.
- 血液透析患者往往对疫苗接种有免疫反应受损.
- 在这个人群中,双价mRNA疫苗的免疫性尚未得到充分理解.
研究的目的:
- 在血液透析患者中评估双价mRNA疫苗的免疫性和潜在反应性.
- 为了比较之前有或没有SARS-CoV-2感染的患者的疫苗反应.
主要方法:
- 对42名血液透析患者进行前性观察队列研究.
- 评估了SARS-CoV-2抗S1 IgG,替代中和抗体 (SNA) 和活病毒中和.
- 第五剂双价疫苗接种前后的测量.
- 对野生型和BA.5 SARS-CoV-2 变种的评估反应.
主要成果:
- 患有先前感染的患者的抗S1IgG和SNA水平明显高于没有感染的患者.
- 在没有先前感染的患者中,双价疫苗接种显著增加了对野生型和BA.5.5的抗体水平和中和能力.
- 在先前感染的患者中,双价疫苗接种没有显著改变抗体水平或诱导额外的免疫反应.
结论:
- 双对应的mRNA疫苗可能会在以前没有感染过SARS-CoV-2的血液透析患者中提高幽默免疫力.
- 需要进行进一步的临床试验,以优化免疫功能低下个体的疫苗接种策略,包括血液透析患者.
更多相关视频
10:25Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection
Published on: June 5, 2021
4.7K
12:09Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
Published on: May 2, 2011
42.9K
相关概念视频
Hemodialysis III: Nursing Management
The nursing management of a patient undergoing hemodialysis includes several critical steps, starting with a thorough assessment before the procedure.Before the Hemodialysis ProcedureFirst, record the patient's vital signs—blood pressure, heart rate, respiratory rate, and temperature—to establish a baseline. This baseline is essential for detecting conditions such as hypotension that could impact the patient's response to dialysis. Document the patient's pre-dialysis weight, as this measurement...
Hemodialysis II: Procedure and Complications
DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
Hemodialysis I: Introduction
Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
Dialysis
Dialysis is a diffusion-based purification process that separates analyte molecules from a complex matrix. This is accomplished by allowing molecules in the solution to pass through a semipermeable membrane into a liquid on the other side. The membrane is usually made of cellulose acetate or cellulose nitrate, and the second liquid must be miscible with the solution. Ions (e.g., chloride or sodium) or organic molecules (e.g., glucose) can pass through the membrane pores, which generally have...
Dialysis
Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
